Companies Dominating the Vogt-Koyanagi-Harada Syndrome Landscape
- Genentech, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Regeneron Pharmaceuticals, Inc.
- Novartis International AG
- AbbVie Inc.
- Johnson & Johnson
- Roche Holding AG
- Sanofi
- Pfizer Inc.
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
Browse Key Market Insights with Data Illustration:
In the News
- Regeneron acquired Checkmate Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel immunotherapies for cancer, for USD 1.1 billion. The acquisition added several new immunotherapy candidates to Regeneron's pipeline, including CMP-001, a bispecific antibody that targets PD-1 and LAG-3, and CMP-002, a T cell engager that targets BCMA.
- Regeneron acquired VXRT Inc., a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, for USD 3.2 billion. The acquisition strengthened Regeneron's vaccine pipeline and added new vaccine candidates for COVID-19 and other infectious diseases.
